Company intelligence / Profile preview
BenevolentAI
London, England, UKbenevolent.com ↗
- Ownership
- Private
- Employees
- ~375
- Development stage
- Phase 1
01
Overview
BEN‑2293 completed Phase IIa study for atopic dermatitis with top-line results anticipated March–April 2023. The ulcerative colitis program advanced a novel candidate to IND-enabling studies within two years from target validation. All pipeline assets are generated using the proprietary Benevolent Platform™.
- Therapeutic areas
- GastroenterologyPulmonologyDermatologyOncologyNeurology
- Modalities
- Small moleculesModality agnostic approaches (platform can address multiple modalities)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Novartis – Framework collaboration agreement on oncology asset development using the Benevolent Platform® for patient stratification and trial optimization.AstraZeneca – Multi-year Target-ID collaboration expanded to systemic lupus erythematosus & heart failure as of January 2022.
Beyond the preview
Go deeper on BenevolentAI.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BenevolentAI.